Skip to main content
Top
Published in: Journal of Bone and Mineral Metabolism 1/2017

01-01-2017 | Case Report

Vitamin D-mediated hypercalcemia in multicentric Castleman’s disease

Authors: Ken-ichiro Tanaka, Ippei Kanazawa, Hitomi Miyake, Shozo Yano, Chika Amano, Noriyoshi Ishikawa, Riruke Maruyama, Toshitsugu Sugimoto

Published in: Journal of Bone and Mineral Metabolism | Issue 1/2017

Login to get access

Abstract

Multicentric Castleman’s disease (MCD) is a rare lymphoproliferative disorder, which represents various symptoms caused by the hyperproduction of interleukin-6 (IL-6). However, case studies of MCD accompanied by hypercalcemia have rarely been reported thus far. A 78-year-old male had generalized fatigue, and his laboratory data revealed elevated serum calcium (Ca) and 1,25-dihydroxyvitamin D [1,25(OH)2D] levels (11.5 mg/dl and 80 pg/ml, respectively), while the serum intact parathyroid hormone level was low (4 pg/ml). Computed tomography showed multicentric lymphadenopathy. The serum IL-6 level was elevated (20.7 pg/ml), and pathological examination of a supraclavicular lymph node specimen led us to diagnose MCD. Moreover, immunostaining analysis showed that vitamin D-activating enzyme 25-hydroxyvitamin D 1-alpha-hydroxylase was expressed in lymph node macrophages. Prednisolone treatment improved the hypercalcemia and decreased the levels of 1,25(OH)2D and IL-6. We first reported a case of vitamin D-mediated hypercalcemia in MCD.
Literature
1.
go back to reference Keller AR, Hochholzer L, Castleman B (1972) Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations. Cancer 29:670–683CrossRefPubMed Keller AR, Hochholzer L, Castleman B (1972) Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations. Cancer 29:670–683CrossRefPubMed
2.
go back to reference Peterson BA, Frizzera G (1993) Multicentric Castleman’s disease. Semin Oncol 20:636–647PubMed Peterson BA, Frizzera G (1993) Multicentric Castleman’s disease. Semin Oncol 20:636–647PubMed
3.
go back to reference Waterston A, Bower M (2004) Fifty years of multicentric Castleman’s disease. Acta Oncol 43:698–704CrossRefPubMed Waterston A, Bower M (2004) Fifty years of multicentric Castleman’s disease. Acta Oncol 43:698–704CrossRefPubMed
4.
go back to reference Roodman GD (2007) Treatment strategies for bone disease. Bone Marrow Transpl 40:1139–1146CrossRef Roodman GD (2007) Treatment strategies for bone disease. Bone Marrow Transpl 40:1139–1146CrossRef
5.
go back to reference Reddy SV, Takahashi S, Dallas M, Williams RE, Neckers L, Roodman GD (1994) Interleukin-6 antisense deoxyoligonucleotides inhibit bone resorption by giant cells from human giant cell tumors of bone. J Bone Miner Res 9:753–757CrossRefPubMed Reddy SV, Takahashi S, Dallas M, Williams RE, Neckers L, Roodman GD (1994) Interleukin-6 antisense deoxyoligonucleotides inhibit bone resorption by giant cells from human giant cell tumors of bone. J Bone Miner Res 9:753–757CrossRefPubMed
6.
go back to reference Washington T, Vora A, Mihailescu D (2010) A case of hypercalcemia associated with Castleman disease. Endocr Pract 16:1007–1011CrossRefPubMed Washington T, Vora A, Mihailescu D (2010) A case of hypercalcemia associated with Castleman disease. Endocr Pract 16:1007–1011CrossRefPubMed
7.
go back to reference Donovan PJ, Sundac L, Pretorius CJ, d’Emden MC, McLeod DS (2013) Calcitriol-mediated hypercalcemia: causes and course in 101 patients. J Clin Endocrinol Metab 98:4023–4029CrossRefPubMed Donovan PJ, Sundac L, Pretorius CJ, d’Emden MC, McLeod DS (2013) Calcitriol-mediated hypercalcemia: causes and course in 101 patients. J Clin Endocrinol Metab 98:4023–4029CrossRefPubMed
8.
go back to reference Kallas M, Green F, Hewison M, White C, Kline G (2010) Rare causes of calcitriol-mediated hypercalcemia: a case report and literature review. J Clin Endocrinol Metab 95:3111–3117CrossRefPubMed Kallas M, Green F, Hewison M, White C, Kline G (2010) Rare causes of calcitriol-mediated hypercalcemia: a case report and literature review. J Clin Endocrinol Metab 95:3111–3117CrossRefPubMed
9.
go back to reference Inui N, Murayama A, Sasaki S, Suda T, Chida K, Kato S, Nakamura H (2001) Correlation between 25-hydroxyvitamin D3 1 alpha-hydroxylase gene expression in alveolar macrophages and the activity of sarcoidosis. Am J Med 110:687–693CrossRefPubMed Inui N, Murayama A, Sasaki S, Suda T, Chida K, Kato S, Nakamura H (2001) Correlation between 25-hydroxyvitamin D3 1 alpha-hydroxylase gene expression in alveolar macrophages and the activity of sarcoidosis. Am J Med 110:687–693CrossRefPubMed
10.
go back to reference Evans KN, Taylor H, Zehnder D, Kilby MD, Bulmer JN, Shah F, Adams JS, Hewison M (2004) Increased expression of 25-hydroxyvitamin D-1alpha-hydroxylase in dysgerminomas: a novel form of humoral hypercalcemia of malignancy. Am J Pathol 165:807–813CrossRefPubMedPubMedCentral Evans KN, Taylor H, Zehnder D, Kilby MD, Bulmer JN, Shah F, Adams JS, Hewison M (2004) Increased expression of 25-hydroxyvitamin D-1alpha-hydroxylase in dysgerminomas: a novel form of humoral hypercalcemia of malignancy. Am J Pathol 165:807–813CrossRefPubMedPubMedCentral
11.
go back to reference Hewison M, Kantorovich V, Liker HR, Van Herle AJ, Cohan P, Zehnder D, Adams JS (2003) Vitamin D-mediated hypercalcemia in lymphoma: evidence for hormone production by tumor-adjacent macrophages. J Bone Miner Res 18:579–582CrossRefPubMed Hewison M, Kantorovich V, Liker HR, Van Herle AJ, Cohan P, Zehnder D, Adams JS (2003) Vitamin D-mediated hypercalcemia in lymphoma: evidence for hormone production by tumor-adjacent macrophages. J Bone Miner Res 18:579–582CrossRefPubMed
12.
go back to reference Ibrahim K, Maghfoor I, Elghazaly A, Bakshi N, Mohamed SY, Aljurf M (2011) Successful treatment of steroid-refractory autoimmune thrombocytopenia associated with Castleman disease with anti-CD-20 antibody (rituximab). Hematol Oncol Stem Cell Ther 4:100–102CrossRefPubMed Ibrahim K, Maghfoor I, Elghazaly A, Bakshi N, Mohamed SY, Aljurf M (2011) Successful treatment of steroid-refractory autoimmune thrombocytopenia associated with Castleman disease with anti-CD-20 antibody (rituximab). Hematol Oncol Stem Cell Ther 4:100–102CrossRefPubMed
13.
go back to reference Yuzuriha A, Saitoh T, Koiso H, Mitsui T, Uchiumi H, Yokohama A, Handa H, Kojima M, Tsukamoto N, Karaswa M, Murakami H, Nojima Y (2011) Successful treatment of autoimmune hemolytic anemia associated with multicentric Castleman disease by anti-interleukin-6 receptor antibody (tocilizumab) therapy. Acta Haematol 126:147–150CrossRefPubMed Yuzuriha A, Saitoh T, Koiso H, Mitsui T, Uchiumi H, Yokohama A, Handa H, Kojima M, Tsukamoto N, Karaswa M, Murakami H, Nojima Y (2011) Successful treatment of autoimmune hemolytic anemia associated with multicentric Castleman disease by anti-interleukin-6 receptor antibody (tocilizumab) therapy. Acta Haematol 126:147–150CrossRefPubMed
14.
Metadata
Title
Vitamin D-mediated hypercalcemia in multicentric Castleman’s disease
Authors
Ken-ichiro Tanaka
Ippei Kanazawa
Hitomi Miyake
Shozo Yano
Chika Amano
Noriyoshi Ishikawa
Riruke Maruyama
Toshitsugu Sugimoto
Publication date
01-01-2017
Publisher
Springer Japan
Published in
Journal of Bone and Mineral Metabolism / Issue 1/2017
Print ISSN: 0914-8779
Electronic ISSN: 1435-5604
DOI
https://doi.org/10.1007/s00774-015-0726-7

Other articles of this Issue 1/2017

Journal of Bone and Mineral Metabolism 1/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.